{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:04:43Z","timestamp":1772269483824,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ymthe.2019.05.020","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T22:33:20Z","timestamp":1559601200000},"page":"1665-1680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis"],"prefix":"10.1016","volume":"27","author":[{"given":"Anand","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisan","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanael","family":"Pruett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Taylor","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Schrump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuong D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.05.020_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ymthe.2019.05.020_bib2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2019.05.020_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the Management of Malignant Pleural Mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.ymthe.2019.05.020_bib5","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.jtho.2018.08.014","article-title":"PL02.09 Nintedanib\u00a0+ Pemetrexed\/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial","volume":"13","author":"Scagliotti","year":"2018","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.21037\/tlcr.2017.04.12","article-title":"In\u00a0vitro experimental models of mesothelioma revisited","volume":"6","author":"Singh","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ymthe.2019.05.020_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2019.05.020_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2019.05.020_bib9","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.05.020_bib10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/92.8.636","article-title":"Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells","volume":"92","author":"Yang","year":"2000","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2019.05.020_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/cgt.2011.86","article-title":"Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed","volume":"19","author":"Li","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2019.05.020_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/cgt.2013.1","article-title":"Gene therapy for malignant mesothelioma: current prospects and challenges","volume":"20","author":"Tagawa","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2019.05.020_bib13","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.020_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2019.05.020_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","article-title":"microRNA Therapeutics in Cancer - An Emerging Concept","volume":"12","author":"Shah","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2019.05.020_bib16","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in Malignant Pleural Mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2019.05.020_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcb.25609","article-title":"MicroRNA Control of p53","volume":"118","author":"Liu","year":"2017","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.ymthe.2019.05.020_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2010.09.005","article-title":"Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53\/MDM2 autoregulatory loop in multiple myeloma development","volume":"18","author":"Pichiorri","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2019.05.020_bib19","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","article-title":"A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy","volume":"285","author":"Komarov","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.05.020_bib20","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/onc.2013.476","article-title":"Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma","volume":"33","author":"Cioce","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2019.05.020_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/onc.2012.28","article-title":"Loss of microRNA-143\/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop","volume":"32","author":"Zhang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2019.05.020_bib22","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1073\/pnas.0808042106","article-title":"p53 represses c-Myc through induction of the tumor suppressor miR-145","volume":"106","author":"Sachdeva","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.020_bib23","doi-asserted-by":"crossref","first-page":"10105","DOI":"10.1158\/0008-5472.CAN-08-1846","article-title":"Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215","volume":"68","author":"Georges","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2019.05.020_bib24","doi-asserted-by":"crossref","first-page":"E1550","DOI":"10.1073\/pnas.1503370112","article-title":"The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation","volume":"112","author":"Jones","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.020_bib25","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib26","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.3390\/ht7030020","article-title":"Genomics and Epigenetics of Malignant Mesothelioma","volume":"7","author":"Sage","year":"2018","journal-title":"High Throughput"},{"key":"10.1016\/j.ymthe.2019.05.020_bib27","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692204","article-title":"The miR-30 family: Versatile players in breast cancer","volume":"39","author":"Yang","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib29","doi-asserted-by":"crossref","first-page":"e6554","DOI":"10.1371\/journal.pone.0006554","article-title":"Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype","volume":"4","author":"R\u00f8e","year":"2009","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"10.1016\/j.ymthe.2019.05.020_bib30","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.21037\/jtd.2017.10.158","article-title":"Overexpressed genes in malignant pleural mesothelioma: implications in clinical management","volume":"10","author":"Barone","year":"2018","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.ymthe.2019.05.020_bib31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.molonc.2016.06.005","article-title":"Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma","volume":"10","author":"Meerang","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib32","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ijrobp.2006.12.018","article-title":"Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests","volume":"67","author":"Kim","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2019.05.020_bib33","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","article-title":"Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications","volume":"25","author":"Suraokar","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/mc.22574","article-title":"Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors","volume":"56","author":"Oweida","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ymthe.2019.05.020_bib35","first-page":"309","article-title":"A Novel Role of Lamins from Genetic Disease to Cancer Biomarkers","volume":"10","author":"Sakthivel","year":"2016","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ymthe.2019.05.020_bib36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.fertnstert.2012.08.002","article-title":"Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration","volume":"98","author":"Galazis","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ymthe.2019.05.020_bib37","doi-asserted-by":"crossref","first-page":"104813","DOI":"10.18632\/oncotarget.20338","article-title":"Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2019.05.020_bib38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1042\/BCJ20160632","article-title":"RUNX transcription factors at the interface of stem cells and cancer","volume":"474","author":"Deltcheva","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2019.05.020_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.08.019","article-title":"Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment","volume":"97","author":"Urso","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/cc.27546","article-title":"Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma","volume":"13","author":"Di Marzo","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ymthe.2019.05.020_bib41","doi-asserted-by":"crossref","first-page":"44232","DOI":"10.18632\/oncotarget.17790","article-title":"Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists","volume":"8","author":"Urso","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2019.05.020_bib42","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.05.020_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcb.240630505","article-title":"NCI-Navy Medical Oncology Branch cell line data base","volume":"24","author":"Phelps","year":"1996","journal-title":"J.\u00a0Cell. Biochem. Suppl."},{"key":"10.1016\/j.ymthe.2019.05.020_bib44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-M","article-title":"Characteristics of nine newly derived mesothelioma cell lines","volume":"59","author":"Pass","year":"1995","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ymthe.2019.05.020_bib45","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2019.05.020_bib46","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1371\/journal.pone.0000898","article-title":"Evidence based selection of housekeeping genes","volume":"2","author":"de Jonge","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.05.020_bib47","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.bjc.6606076","article-title":"The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis","volume":"104","author":"Gee","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2019.05.020_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jso.2930310402","article-title":"Tumor measurement in the nude mouse","volume":"31","author":"Euhus","year":"1986","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.ymthe.2019.05.020_bib49","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-09-2291","article-title":"miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma","volume":"70","author":"Liu","year":"2010","journal-title":"Cancer Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619302679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619302679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:54:45Z","timestamp":1761501285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619302679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1525001619302679"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}